Tucidinostat

Generic Name: Tucidinostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Phase 1

Conditions: Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

Interventions: Biological: Decitabine-primed Tandem CAR19/20 engineered T cells
Drug: Chidamide and Decitabine
Drug: Chidamide
Drug: Decitabine

First Posted Date: 2020-09-17

Last Posted Date: 2020-12-04

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 80

Registration Number: NCT04553393

Locations: 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

Not Applicable

Conditions: Lymphoma

Interventions: Drug: Chidamide

First Posted Date: 2020-08-13

Last Posted Date: 2020-08-13

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 76

Registration Number: NCT04511351

Locations: 🇨🇳
National Cancer Center, Cancer Hospital, Chinese Academy of Medical Scienses, Beijing, Beijing, China

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Phase 2

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Azacitidine
Drug: Chidamide

First Posted Date: 2020-07-21

Last Posted Date: 2022-04-20

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 28

Registration Number: NCT04480125

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Tucidinostat
Drug: Exemestane
Drug: Ovarian function suppression

First Posted Date: 2020-07-09

Last Posted Date: 2023-10-17

Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 30

Registration Number: NCT04465097

Locations: 🇨🇳
The first affiliated hospital of Sun Yat-Sen university, Guangzhou, Guangdong, China

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Phase 1

Recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: Chidamide
Drug: Decitabine
Drug: Camrelizumab

First Posted Date: 2020-04-07

Last Posted Date: 2020-04-07

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 100

Registration Number: NCT04337606

Locations: 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Phase 2

Recruiting

Conditions: Cutaneous T-cell Lymphoma

Interventions: Drug: Sintilimab
Drug: Chidamide

First Posted Date: 2020-03-05

Last Posted Date: 2020-03-05

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 52

Registration Number: NCT04296786

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Chidamide
Drug: Camrelizumab
Drug: Decitabine

First Posted Date: 2020-01-18

Last Posted Date: 2020-08-14

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 100

Registration Number: NCT04233294

Locations: 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
Drug: Tucidinostat
Drug: Placebo

First Posted Date: 2020-01-18

Last Posted Date: 2024-12-05

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 423

Registration Number: NCT04231448

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳
Shanghai JiaoTong University School of Medicine，Ruijin Hospital, Shanghai, Shanghai, China

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Phase 2

Not yet recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Sintilimab
Drug: Chidamide
Drug: Azacidine

First Posted Date: 2019-08-12

Last Posted Date: 2021-03-09

Lead Sponsor: Peking University

Target Recruit Count: 30

Registration Number: NCT04052659

Locations: 🇨🇳
Beijing, Beijing, Beijing, China

Biomarker Guided Treatment in DLBCL

Phase 2

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ibrutinib
Drug: Lenalidomide
Drug: chidamide
Drug: decitabine

First Posted Date: 2019-07-19

Last Posted Date: 2020-11-19

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 128

Registration Number: NCT04025593

Locations: 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy